Diaceutics (GB:DXRX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Diaceutics PLC is expanding its US commercial activities by executing multiple data partnership agreements, contributing to a first-year contract value of £1.13 million. These partnerships are expected to increase revenue and Annual Recurring Revenue by leveraging partner sales teams to sell high-margin data products like DXRX Signal. The company aims to broaden its customer base, tapping into new segments and pharmaceutical brands.
For further insights into GB:DXRX stock, check out TipRanks’ Stock Analysis page.
